Celgene $239 Million Securities Class Action Lawsuit Settlement, Investors Can File Claims Until April 13, 2026
The Celgene $239 Million Securities Class Action Settlement provides compensation to investors who purchased Celgene common stock between April 27, 2017 and April 27, 2018. If you bought Celgene shares during this period, you must file a claim by April 13, 2026 at www.CelgeneSecuritiesLitigation.com to receive payment from the settlement fund.
What Is the Celgene Securities Settlement About?
Celgene Corporation faces allegations of making false and misleading statements about its pharmaceutical products and drug candidates. The securities fraud lawsuit claims the biopharmaceutical company artificially inflated its stock price by concealing critical information about three key drugs: GED-0301 (a Crohn’s disease treatment), Otezla (a psoriasis drug), and Ozanimod (now marketed as Zeposia for multiple sclerosis).
Lead Plaintiff AMF Tjänstepension AB, a Swedish pension fund, filed the lawsuit on behalf of all affected investors. The case alleged that Celgene and two senior executives failed to disclose that GED-0301 showed insufficient efficacy in trials and had a higher likelihood of failure than publicly stated.
Bristol-Myers Squibb, which acquired Celgene for $80.3 billion in November 2019, agreed to the $239 million settlement to resolve the nearly eight-year litigation. The settlement received preliminary court approval on December 19, 2025.
The Allegations Against Celgene
According to court filings, Celgene allegedly overstated the revenue potential for Otezla and Ozanimod as the company faced the looming loss of patent protection for Revlimid, its blockbuster multiple myeloma drug. Internal warnings reportedly indicated that Otezla would generate substantially less revenue than promised to investors.
On October 19, 2017, Celgene revealed it would abandon the GED-0301 program and record a $1.6 billion impairment charge. Celgene stock fell $14.63 per share to close at $121.33 on October 20, 2017—a one-day decline of nearly 11%.
The lawsuit claims investors purchased Celgene common stock at artificially inflated prices based on these alleged misrepresentations and suffered damages when the truth emerged.
Who Qualifies for the Celgene Settlement?
You’re included in the Settlement Class if you purchased or acquired Celgene Corporation common stock between April 27, 2017 and April 27, 2018, inclusive, and were damaged as a result.
Both individual investors and entities qualify as class members. This includes corporations, trusts, estates, and partnerships that held Celgene stock during the class period.
Excluded from the Settlement Class
Certain individuals and entities cannot participate in the settlement:
- Celgene’s directors and officers during the class period and their immediate family members
- Celgene’s subsidiaries, parents, and affiliates
- Anyone who previously requested exclusion from the class in July 2022
- The presiding judge and defendants
Investors who held shares solely through ERISA-covered employee benefit or retirement plans cannot file individual claims. Plan trustees must submit claims on behalf of ERISA plans.
How to Verify Your Eligibility
Review your brokerage statements from April 27, 2017 through April 27, 2018. Look for any purchases or acquisitions of Celgene common stock during this period. If you purchased shares during the class period and held them when corrective disclosures occurred, you may have suffered compensable losses.
Each legal entity or separately managed account must submit a separate claim. Authorized representatives can submit claims on behalf of beneficial owners, but executors, administrators, guardians, and trustees must provide proof of authority.
How Much Money Can Investors Receive?
The gross settlement fund totals $239,000,000. After deductions for legal fees, litigation expenses, and administration costs, the remaining net settlement fund will be distributed among all approved claimants.
Class Counsel intends to request up to 30% of the settlement fund (approximately $71.7 million) for attorney fees, plus up to $5.75 million for litigation expenses. The lead plaintiff may receive a service award of up to $5,000 for representing the class.
Former Celgene shareholders could receive approximately $159.3 million collectively after legal fees and costs are deducted, according to court documents filed in November 2025.
Payment Calculation and Distribution
Your payment depends on how many Celgene shares you purchased during the class period, when you bought them, and when you sold them. The settlement uses a recognized loss calculation based on the Plan of Allocation approved by the court.
The Claims Administrator will review each claim to determine your recognized loss and your pro rata share of the net settlement fund. Payments will only be made after the court grants final approval and any appeals are resolved.
Similar celsius drink settlements have provided meaningful compensation to affected investors, though individual payment amounts vary based on the total number of valid claims submitted.
How to File Your Claim for Celgene Settlement
You must submit a Proof of Claim and Release Form by April 13, 2026 to receive compensation. Here’s your complete guide:
Step 1: Access the Claim Form
Visit www.CelgeneSecuritiesLitigation.com to file your claim online or download a PDF claim form. You can also request a claim form by calling 855-648-0893 or writing to:
Celgene Corp. Securities Litigation
c/o JND Legal Administration
P.O. Box 91422
Seattle, WA 98111
Step 2: Gather Required Documentation
You’ll need specific information about your Celgene stock transactions:
- Purchase, acquisition, and sale information including dates, number of shares, and prices paid
- Documentation supporting your transactions (brokerage statements, confirmation slips, or authorized statements from your financial institution)
- Proof of holdings at the beginning and end of relevant periods
- Your Social Security number (last four digits) or full taxpayer identification number
Self-created documents are not acceptable. Screenshots from online trading platforms may be accepted if they include all required transaction details and clearly identify the account owner.
Step 3: Complete and Submit Your Claim
Fill out the claim form completely and accurately. Provide all requested information about your Celgene stock purchases and sales during the class period.
Submit your completed claim form online at www.CelgeneSecuritiesLitigation.com or mail it to the address above. If mailing, ensure your claim form is postmarked no later than April 13, 2026.
Missing the deadline means you’ll forfeit your right to receive settlement compensation, though you’ll still be bound by the settlement terms and unable to pursue separate legal action.
What Happens After You File Your Claim?
The Claims Administrator will review your submission to verify it meets all requirements. The administrator may contact you if additional information or documentation is needed to process your claim.
If the Claims Administrator proposes to reject your claim in whole or part, you’ll receive written notice explaining the reasons. You’ll have the right to request court review of any rejection.
Timeline for Receiving Payment
The settlement must receive final court approval before any payments are distributed. Key dates include:
Settlement Hearing: The court will hold a final approval hearing to determine whether the settlement is fair, reasonable, and adequate.
Appeals Period: After court approval, there’s a waiting period for any appeals to be filed and resolved.
Payment Distribution: Once the settlement becomes effective and all appeals are resolved, the Claims Administrator will distribute payments to all approved claimants within 60 days.
Given the typical timeline for securities class action settlements, approved claimants should expect to receive payments sometime in 2026 or early 2027, depending on whether appeals are filed.
Understanding Your Rights Under the Settlement
As a class member, you have several options:
Submit a Claim and Receive Benefits
File a valid claim by April 13, 2026 to receive your share of the settlement. By participating, you’ll release all claims against Celgene and Bristol-Myers Squibb related to the allegations in this lawsuit.
Exclude Yourself from the Settlement
If you want to preserve your right to sue Celgene independently, you can request exclusion from the settlement. However, the deadline for exclusion requests has passed—it was January 23, 2026.
Object to the Settlement
Class members who don’t exclude themselves can object to the settlement terms if they believe the settlement is unfair. Objections must be filed with the court and mailed to designated addresses.
Do Nothing
If you take no action, you won’t receive any settlement payment. However, you’ll still be bound by the court’s judgment and give up your right to bring your own lawsuit about these claims.
Securities Fraud Protections for Investors
The Securities Exchange Act of 1934 provides crucial protections against fraudulent or misleading statements by publicly traded companies. Section 10(b) and Rule 10b-5 prohibit companies from making false statements or omitting material facts that could mislead investors.
When companies violate these regulations, investors who purchased stock at artificially inflated prices can seek compensation through class action lawsuits. These cases help hold corporations accountable for misrepresenting their financial condition or business prospects.
The Litigation Journey
This Celgene case demonstrates the extensive work required to achieve securities settlements. The litigation spanned nearly eight years and included:
- Production of over 4.8 million pages of documents
- Depositions of 21 fact witnesses and 10 expert witnesses
- Multiple summary judgment motions with over 400 exhibits
- Two mediation sessions before reaching settlement
Class certification was granted on November 29, 2020, confirming the case could proceed as a class action on behalf of all affected investors.
Frequently Asked Questions
What drugs were involved in the Celgene allegations?
The lawsuit focused on three pharmaceutical products: GED-0301 (a late-stage Crohn’s disease treatment that Celgene ultimately abandoned), Otezla (a psoriasis medication), and Ozanimod (a multiple sclerosis drug now marketed as Zeposia). Celgene allegedly misrepresented the prospects and revenue potential for these drugs to investors.
Do I need proof of purchase to file a claim?
Yes, you must provide documentation supporting your Celgene stock transactions. Acceptable proof includes brokerage statements, trade confirmations, or authorized statements from financial institutions showing your purchase and sale information. Self-created spreadsheets or documents are not sufficient.
What if I sold my Celgene shares before Bristol-Myers Squibb acquired the company?
You can still file a claim if you purchased Celgene stock during the class period (April 27, 2017 to April 27, 2018) and were damaged as a result. Your recognized loss calculation will be based on when you purchased and sold your shares relative to corrective disclosures.
How long will it take to receive my settlement payment?
Payments will be distributed within 60 days after the settlement becomes effective. The settlement becomes effective after the court grants final approval and any appeals are resolved. This typically takes several months to over a year from preliminary approval.
Can I still file a claim if I inherited Celgene stock?
Yes, executors, administrators, and legal representatives can submit claims on behalf of estates or beneficiaries who held Celgene stock during the class period. You must provide proof of your authority to file on behalf of the estate or beneficiary.
What happens to unclaimed settlement funds?
Any settlement funds that remain unclaimed after the distribution process is complete will be handled according to the court-approved plan of allocation. Typically, unclaimed funds may be redistributed to existing claimants or donated to appropriate charitable organizations.
Will participating in this settlement affect my taxes?
Settlement payments may have tax consequences. The settlement administrator is not providing tax advice, and each class member’s tax obligations depend on their individual circumstances. Consult a tax professional about how settlement payments should be reported on your tax return.
Last Updated: January 21, 2026
Disclaimer: This article provides general information about the Celgene $239 Million Securities Class Action Settlement and should not be considered legal or investment advice.
Don’t miss your deadline: If you purchased Celgene stock between April 27, 2017 and April 27, 2018, file your claim by April 13, 2026 at www.CelgeneSecuritiesLitigation.com to secure your share of the $239 million settlement fund.
Stay informed, stay protected. — AllAboutLawyer.com
About the Author
Sarah Klein, JD, is a licensed attorney and legal content strategist with over 12 years of experience across civil, criminal, family, and regulatory law. At All About Lawyer, she covers a wide range of legal topics — from high-profile lawsuits and courtroom stories to state traffic laws and everyday legal questions — all with a focus on accuracy, clarity, and public understanding.
Her writing blends real legal insight with plain-English explanations, helping readers stay informed and legally aware.
Read more about Sarah